Package Leaflet: Information for the User
Darunavir Mylan 600 mg Film-Coated Tablets EFG
darunavir
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Package Leaflet
What is Darunavir Mylan?
Darunavir Mylan contains the active substance darunavir. Darunavir is an antiretroviral medicine used to treat HIV infection. It belongs to a group of medicines called protease inhibitors. Darunavir reduces the amount of HIV in your body. This will improve your immune system and reduce the risk of diseases associated with HIV infection.
What is it used for?
Darunavir is used to treat adults and children from 3 years of age and at least 15 kg in weight who are infected with HIV and have already used other antiretroviral medicines.
Darunavir must be taken with a low dose of ritonavir and other HIV medicines. Your doctor will discuss with you which combination of medicines is best for you.
Do not take Darunavir Mylan
Do not combine Darunavir Mylan with any of the following medicines
If you are taking any of these medicines, consult your doctor to change to another medicine.
Do not combine darunavir with products that contain St. John's Wort (Hypericum perforatum).
Warnings and precautions
Consult your doctor, pharmacist, or nurse before you start taking Darunavir Mylan.
Darunavir does not cure HIV infection. While you are taking this medicine, you may still develop infections or other illnesses associated with HIV. Keep in regular contact with your doctor.
People taking darunavir may develop skin reactions. It is not common for the skin reaction to be severe or life-threatening. However, if you develop a skin reaction, please contact your doctor.
Patient taking darunavir and raltegravir (for HIV infection) may more frequently experience rash (generally mild or moderate) than patients taking either of these medicines separately.
Tell your doctor about your situation BEFORE and DURING treatment
Make sure you check the following points and tell your doctor if any of them apply to you.
Some of the many risk factors for developing this disease include the duration of combination antiretroviral therapy, the use of corticosteroids, alcohol consumption, severe immunosuppression, and a higher body mass index. The signs of osteonecrosis are pain, discomfort, and stiffness in the joints (especially the hip, knees, and shoulders) and difficulty walking. If you notice any of these symptoms, inform your doctor.
Elderly population
Darunavir Mylan has only been used in a limited number of patients aged 65 years or older. If you belong to this age group, please consult your doctor to see if you can use Darunavir Mylan.
Paediatric population
Darunavir is not used in children under 3 years of age or weighing less than 15 kg.
Taking Darunavir Mylan with other medicines
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
Some medicines must not be takenwith darunavir. The list can be found in the section "Do not combine Darunavir Mylan with any of the following medicines:"
In most cases, darunavir can be combined with HIV medicines from other classes (e.g., NRTIs [nucleoside reverse transcriptase inhibitors], NNRTIs [non-nucleoside reverse transcriptase inhibitors], CCR5 antagonists, and fusion inhibitors). However, darunavir has not been tested with all protease inhibitors (PIs) and must not be used with other HIV PIs. In some cases, it may be necessary to change the dose of the other medicines. Therefore, if you are taking other HIV medicines, always inform your doctor and carefully follow their instructions on which medicines can be combined.
The following products may reduce the effect of darunavir. Inform your doctor if you are taking:
Darunavir may also affect the action of other medicines. Inform your doctor if you are taking:
In certain cases, it may be necessary to modify the dose of some medicines because when combined, the therapeutic or adverse effects of these or darunavir may be affected.
Tell your doctor if you are taking:
This is nota complete list of medicines. Inform your doctor about all the medicines you are taking.
Taking Darunavir Mylan with food and drink
See section 3 "How to take Darunavir Mylan".
Pregnancy and breast-feeding
Inform your doctor immediately if you are pregnant, plan to become pregnant, or are breast-feeding. Pregnant or breast-feeding women should not take Darunavir Mylan with ritonavir unless their doctor has specifically told them to do so. Pregnant or breast-feeding women should not take darunavir with cobicistat.
It is recommended that women infected with HIV do not breast-feed their babies because there is a possibility that the babies could be infected with HIV through their milk, and due to the unknown effects of the medicine on the baby.
Consult your doctor or pharmacist before using any medicine.
Driving and using machines
Do not drive or operate machines if you feel dizzy after taking Darunavir Mylan.
Darunavir Mylan contains less than 1 mmol of sodium (23 mg) per dose, which is essentially "sodium-free".
Follow the administration instructions for the medicine described in this leaflet or as indicated by your doctor, pharmacist, or nurse. In case of doubt, ask your doctor, pharmacist, or nurse.
Do not stop taking Darunavir Mylan or ritonavir without consulting your doctor first, even if you feel better.
Once treatment has started, the dose or form of the dose should not be changed, nor should treatment be interrupted without consulting a doctor.
Dose for adults who have not taken antiretroviral medications before (to be determined by your doctor)
You will require a different dose of darunavir, which cannot be administered with these 600-milligram tablets. Other doses of Darunavir Mylan are available.
Dose for adults who have taken antiretroviral medications before (to be determined by your doctor)
The dose is:
Or
Talk to your doctor about which dose is correct for you.
Instructions for adults
Dose for children from 3 years of age, weighing at least 15 kilograms, who have not taken antiretroviral medications before (to be determined by your child's doctor)
The doctor will calculate the correct daily dose based on the child's weight (see the following table). This dose should not exceed the recommended adult dose, which is 800 milligrams of darunavir along with 100 milligrams of ritonavir once a day.
The doctor will inform you about what amount of Darunavir Mylan tablets and what amount of ritonavir (capsules, tablets, or solution) the child should take.
Oral solution of ritonavir: 80 milligrams per milliliter
Dose for children from 3 years of age, weighing at least 15 kilograms, who have taken antiretroviral medications before (to be determined by your child's doctor)
The doctor will establish the correct dose based on the child's weight (see the following table). The doctor will determine if the once-daily or twice-daily dose is appropriate for the child. This dose should not exceed the recommended adult dose, which is 600 milligrams of darunavir along with 100 milligrams of ritonavir twice a day or 800 milligrams of darunavir along with 100 milligrams of ritonavir once a day. The doctor will inform you about what amount of Darunavir Mylan tablets and what amount of ritonavir (capsules, tablets, or solution) the child should take. Lower-concentration tablets are available to achieve the appropriate dosing regimen. Other presentations of this medication may be more suitable for children; ask your doctor or pharmacist.
Dose twice a day
Dose once a day
Instructions for children
If you take more Darunavir Mylan than you should
Inform your doctor, pharmacist, or nurse immediately.
If you forget to take Darunavir Mylan
If you realize within 6 hours, take the missed dose immediately. Always take it with ritonavir and with food. If you realize after 6 hours, skip that dose and continue with the next dose as usual. Do not take a double dose to make up for missed doses.
Do not stop taking Darunavir Mylan without talking to your doctor first
HIV medications can make you feel better. Even if you feel better, do not stop taking Darunavir Mylan. Consult your doctor first.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
During HIV treatment, weight gain and increased lipid and glucose levels may occur. This is associated, in part, with the recovery of health and lifestyle, and in the case of blood lipids, sometimes due to the medications used to treat HIV. Your doctor will perform tests to detect these changes.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Tell your doctor if you develop any of the following side effects.
Liver problems have been reported, which can sometimes be severe. Your doctor will perform blood tests before starting treatment with darunavir. If you have chronic hepatitis B or C infection, your doctor will perform blood tests more frequently because you are more likely to develop liver problems. Talk to your doctor about the signs and symptoms of liver problems. These signs and symptoms can include, among others: yellowing of the skin or the whites of the eyes, dark urine (tea-colored), pale stools, nausea, vomiting, loss of appetite, or pain, itching, or discomfort in the right upper abdomen.
Skin rash (more frequent when used in combination with raltegravir), itching. The skin rash is usually mild to moderate. A skin rash can also be a symptom of a rare and serious situation. Therefore, it is essential to talk to your doctor if you develop a rash. Your doctor will advise you on how to control the symptoms or if you should stop using darunavir.
Other serious side effects were diabetes (frequent) and pancreatitis (infrequent).
Very common side effects (may affect more than 1 in 10 patients)
Common side effects (may affect up to 1 in 10 patients)
Uncommon side effects (may affect up to 1 in 100 patients)
Rare side effects (may affect up to 1 in 1,000 patients)
Some side effects are typical of HIV medications that belong to the same family as darunavir. These are:
Reporting side effects
If you experience side effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the box and bottle, after EXP. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
In the case of bottles: Once opened, use the product within 100 days.
Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any medication you no longer need. This will help protect the environment.
Darunavir Mylan composition
Appearance of Darunavir Mylan and package contents
The 600-milligram Darunavir Mylan film-coated tablets are white or almost white, oval, with two curved sides, marked with an "M" on one face and "DV5" on the other.
The 600-milligram Darunavir Mylan film-coated tablets are available in blisters containing 30 and 60 tablets and in plastic bottles containing 30, 60, and 90 tablets.
Only some pack sizes may be marketed.
Marketing authorization holder
Mylan S.A.S.
117 Allee des Parcs
69800 Saint Priest
France
Manufacturer
Mylan Hungary Kft
H-2900 Komárom, Mylan utca 1
Hungary
McDermott Laboratories Limited, trading as Gerard Laboratories, 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ireland
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Mylan bvba/sprl Tel: + 32 (0)2 658 61 00 | Lietuva BGP Products UAB Tel: +370 5 205 1288 |
???????? ?????? ???? Tel: +359 2 44 55 400 | Luxembourg/Luxemburg Mylan bvba/sprl Tel: + 32 (0)2 658 61 00 (Belgique/Belgien) |
Ceská republika Mylan Pharmaceuticals.s.r.o. Tel: + 420 222 004 400 | Magyarország Mylan EPD Kft Tel: + 36 1 465 2100 |
Danmark Mylan AB Tlf: + 46 855 522 750 (Sverige) | Malta V.J. Salomone Pharma Ltd Tel: + 356 21 22 01 74 |
Deutschland Mylan dura GmbH Tel: + 49-(0) 6172 888 01 | Nederland Mylan BV Tel: + 31 (0)20 426 3300 |
Eesti BGP Products Switzerland GmbH Eesti filiaal Tel: + 372 6363 052 | Norge Mylan AB Tel: + 46 855 522 750 (Sverige) |
Ελλ?da Generics Pharma Hellas ΕΠΕ Τηλ: +30 210 993 6410 | Österreich Arcana Arzneimittel GmbH Tel: +43 1 416 2418 |
España Mylan Pharmaceuticals, S.L Tel: + 34 900 102 712 | Polska Mylan Healthcare Sp. z.o.o. Tel: + 48 22 546 64 00 |
France Mylan S.A.S Tel: +33 4 37 25 75 00 | Portugal Mylan, Lda. Tel: + 351 21 412 72 56 |
France Mylan S.A.S Tel: +33 4 37 25 75 00 | România BGP Products SRL Tel: +40 372 579 000 |
Ireland Mylan Ireland Tel: +353 (0) 87 1694982 | Slovenija GSP Proizvodi d.o.o. Tel: + 386 1 236 31 85 |
Ísland Mylan AB Tel: + 46 855 522 750 (Svíþjóð) | Slovenská republika Mylan s.r.o. Tel: +421 2 199 100 |
Italia Mylan S.p.A Tel: + 39 02 612 46921 | Suomi/Finland Mylan OY Puh/Tel: + 358 20 720 9555 |
Italia Mylan S.p.A Tel: + 39 02 612 46921 | Sverige Mylan AB Tel: + 46 855 522 750 |
Latvija BGP Products SIA Tel: +371 676 055 80 | United Kingdom Generics [UK] Ltd Tel: +44 1707 853000 |
Date of last revision of this leaflet: {MM/AAAA}.
Other sources of information
Detailed information about this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.